Bionano Genomics (BNGO) 10-Q 7 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 02, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Trading Symbol	BNGO
Entity Registrant Name	Bionano Genomics, Inc.
Entity Central Index Key	1,411,690
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		10,032,687

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 20,657,038	$ 1,021,897
Accounts receivable, net	4,000,924	3,352,214
Inventory	2,614,812	1,693,742
Prepaid expenses and other current assets	1,347,774	1,071,512
Total current assets	28,620,548	7,139,365
Property and equipment, net	2,049,256	3,005,788
Total assets	30,669,804	10,145,153
Current liabilities:
Accounts payable	2,363,752	2,302,964
Accrued expenses	2,815,290	3,508,894
Deferred revenue	335,604	211,697
Preferred stock warrant liability	0	3,898,944
Current portion of long-term debt	0	6,729,752
Total current liabilities	5,514,646	16,652,251
Long-term debt, net of current portion	9,008,337	0
Long-term deferred revenue	144,602	142,929
Other non-current liabilities	767,197	567,047
Total liabilities	15,434,782	17,362,227
Commitments and contingencies (Note 9)	0	0
Stockholders’ equity (deficit):
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of September 30, 2018 and December 31, 2017	0	0
Common stock, $0.0001 par value, 200,000,000 and 243,160,120 shares authorized at September 30, 2018 and December 31, 2017, respectively; 10,032,687 and 77,257 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	1,002	8
Additional paid-in capital	81,584,992	4,038,817
Accumulated deficit	(66,350,972)	(54,266,036)
Total stockholders’ equity (deficit)	15,235,022	(50,227,211)
Total liabilities, convertible preferred stock, and stockholders’ equity (deficit)	30,669,804	10,145,153
Series A Convertible Preferred Stock
Current liabilities:
Convertible preferred stock	0	61,847
Series B Convertible Preferred Stock
Current liabilities:
Convertible preferred stock	0	842,845
Series B-1 Convertible Preferred Stock
Current liabilities:
Convertible preferred stock	0	359,593
Series C Convertible Preferred Stock
Current liabilities:
Convertible preferred stock	0	5,547,841
Series D Convertible Preferred Stock
Current liabilities:
Convertible preferred stock	0	4,838,379
Series D-1 Convertible Preferred Stock
Current liabilities:
Convertible preferred stock	$ 0	$ 31,359,632

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	200,000,000	243,160,120
Common stock, shares issued	10,032,687	77,257
Common stock, shares outstanding	10,032,687	77,257
Series A Convertible Preferred Stock
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	0	418,767
Convertible preferred stock, shares issued	0	345,587
Convertible preferred stock, shares outstanding	0	345,587
Series B Convertible Preferred Stock
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	0	8,101,042
Convertible preferred stock, shares issued	0	8,058,170
Convertible preferred stock, shares outstanding	0	8,058,170
Series B-1 Convertible Preferred Stock
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	0	7,523,734
Convertible preferred stock, shares issued	0	3,437,950
Convertible preferred stock, shares outstanding	0	3,437,950
Series C Convertible Preferred Stock
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	0	23,357,047
Convertible preferred stock, shares issued	0	23,357,047
Convertible preferred stock, shares outstanding	0	23,357,047
Series D Convertible Preferred Stock
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	0	52,835,720
Convertible preferred stock, shares issued	0	20,652,486
Convertible preferred stock, shares outstanding	0	20,652,486
Series D-1 Convertible Preferred Stock
Convertible preferred stock, par value	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	0	125,808,667
Convertible preferred stock, shares issued	0	66,141,257
Convertible preferred stock, shares outstanding	0	66,141,257

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues:
Total revenue	$ 2,828,704	$ 2,743,056	$ 7,987,198	$ 6,659,920
Cost of revenue:
Total cost of revenue	3,068,332	1,690,223	5,723,211	4,534,340
Operating expense:
Research and development	2,505,137	2,967,073	6,962,696	9,551,687
Selling, general and administrative	3,224,075	3,116,922	9,617,814	10,553,348
Total operating expense	5,729,212	6,083,995	16,580,510	20,105,035
Loss from operations	(5,968,840)	(5,031,162)	(14,316,523)	(17,979,455)
Other income (expense):
Interest expense	(404,437)	(145,308)	(1,114,053)	(431,403)
Change in fair value of preferred stock warrants and expirations	1,520,159	154,469	3,991,081	1,108,362
Other expense	(75,957)	(68,189)	(639,137)	(125,324)
Total other income (expense)	1,039,765	(59,028)	2,237,891	551,635
Loss before income taxes	(4,929,075)	(5,090,190)	(12,078,632)	(17,427,820)
Benefit (provision) for income taxes	2,978	4,738	(6,304)	(17,620)
Net loss	$ (4,926,097)	$ (5,085,452)	$ (12,084,936)	$ (17,445,440)
Net loss per share, basic and diluted	$ (0.63)	$ (1.74)	$ (1.99)	$ (6.68)
Weighted-average common shares outstanding basic and diluted	7,778,605	2,920,839	6,079,285	2,609,863
Product Revenue
Revenues:
Total revenue	$ 2,700,162	$ 2,604,215	$ 7,618,407	$ 6,213,496
Cost of revenue:
Total cost of revenue	3,064,661	1,643,504	5,708,704	4,462,365
Other Revenue
Revenues:
Total revenue	128,542	138,841	368,791	446,424
Cost of revenue:
Total cost of revenue	$ 3,671	$ 46,719	$ 14,507	$ 71,975

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)	Total	Initial Public Offering	Initial Public OfferingConvertible Notes	Common Stock	Common StockInitial Public Offering	Common StockInitial Public OfferingConvertible Notes	Additional Paid-in Capital	Additional Paid-in CapitalInitial Public Offering	Additional Paid-in CapitalInitial Public OfferingConvertible Notes	Accumulated Deficit	Series A Convertible Preferred Stock	Series A Convertible Preferred StockInitial Public Offering	Series B Convertible Preferred Stock	Series B Convertible Preferred StockInitial Public Offering	Series B-1 Convertible Preferred Stock	Series B-1 Convertible Preferred StockInitial Public Offering	Series C Convertible Preferred Stock	Series C Convertible Preferred StockInitial Public Offering	Series D Convertible Preferred Stock	Series D Convertible Preferred StockInitial Public Offering	Series D-1 Convertible Preferred Stock	Series D-1 Convertible Preferred StockInitial Public Offering
Beginning Balance at Dec. 31, 2016	$ (27,258,972)			$ 7			$ 3,641,693			$ (30,900,672)
Convertible Preferred Stock (Shares), Beginning Balance at Dec. 31, 2016											345,587		8,058,170		3,437,950		23,357,047		20,652,486		29,166,671
Convertible Preferred Stock, Beginning Balance at Dec. 31, 2016											$ 61,847		$ 842,845		$ 359,593		$ 5,547,841		$ 4,838,379		$ 13,766,022
Beginning Balance, Shares at Dec. 31, 2016				70,178
Issuance of convertible preferred stock																					$ 17,593,610
Issuance of convertible preferred stock, Shares																					36,974,586
Stock option exercises	14,295			$ 1			14,294
Stock option exercises, Shares				7,079
Stock-based compensation expense	382,830						382,830
Net loss	(23,365,364)									(23,365,364)
Ending Balance at Dec. 31, 2017	(50,227,211)			$ 8			4,038,817			(54,266,036)
Convertible Preferred Stock (Shares), Ending Balance at Dec. 31, 2017											345,587		8,058,170		3,437,950		23,357,047		20,652,486		66,141,257
Convertible Preferred Stock, Ending Balance at Dec. 31, 2017											$ 61,847		$ 842,845		$ 359,593		$ 5,547,841		$ 4,838,379		$ 31,359,632
Ending Balance, Shares at Dec. 31, 2017				77,257
Stock option exercises	3,499						3,499
Stock option exercises, Shares				1,856
IPO Units		$ 19,389,978			$ 386			$ 19,389,592
IPO Units, Shares					3,864,000
Conversion of preferred stock and convertible debt		$ 43,010,137	$ 14,898,327		$ 285	$ 323		$ 43,009,852	$ 14,898,004			$ (61,847)		$ (842,845)		$ (359,593)		$ (5,547,841)		$ (4,838,379)		$ (31,359,632)
Conversion of preferred stock and convertible debt Shares					2,850,280	3,239,294						(345,587)		(8,058,170)		(3,437,950)		(23,357,047)		(20,652,486)		(66,141,257)
Conversion of preferred stock warrants into common stock warrants	84,676						84,676
Stock-based compensation expense	160,551						160,551
Net loss	(12,084,936)									(12,084,936)
Ending Balance at Sep. 30, 2018	$ 15,235,022			$ 1,002			$ 81,584,992			$ (66,350,972)
Convertible Preferred Stock (Shares), Ending Balance at Sep. 30, 2018											0		0		0		0		0		0
Ending Balance, Shares at Sep. 30, 2018				10,032,687

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)	12 Months Ended
	Dec. 31, 2017USD ($)
Series D-1 Convertible Preferred Stock
Stock issuance cost	$ 154,191

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Operating activities:
Net loss			$ (12,084,936)	$ (17,445,440)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization expense	$ 391,246	$ 240,551	1,169,801	964,932
Change in fair value of preferred stock warrants and expirations	(1,520,159)	(154,469)	(3,991,081)	(1,108,362)
Stock-based compensation			160,551	241,971
Provision for bad debt expense			(262,000)	0
Inventory write-off			1,287,000	364,437
Accretion of debt discount			121,984	66,241
Loss on debt extinguishment			342,164	0
Changes in operating assets and liabilities:
Accounts receivable			(386,710)	(692,637)
Inventory			(2,101,453)	(442,849)
Prepaid expenses and other current assets			(276,263)	241,032
Accounts payable			60,788	320,184
Accrued expenses and other liabilities			106,476	(518,298)
Net cash used in operating activities			(15,853,679)	(18,008,789)
Investing activities:
Purchases of property and equipment			(319,885)	(736,063)
Net used in investing activities			(319,885)	(736,063)
Financing activities:
Repayment of notes payable			(7,447,571)	0
Proceeds from issuance of long-term debt, net of offering costs			9,532,957	0
Proceeds from issuance of convertible note, net of offering costs			14,329,843	0
Proceeds from issuance of preferred stock and warrants, net of offering costs			0	16,131,764
Proceeds from Initial Public Offering, net of offering costs			19,389,978	0
Proceeds from option exercises			3,499	1,500
Net cash provided by financing activities			35,808,706	16,133,264
Net increase (decrease) in cash and cash equivalents			19,635,142	(2,611,589)
Cash and cash equivalents at beginning of period			1,021,897	5,249,620	$ 5,249,620
Cash and cash equivalents at end of period	$ 20,657,038	$ 2,633,904	20,657,038	2,633,904	$ 1,021,897
Supplemental schedule on non-cash transactions:
Conversion of Convertible Note into Common Stock			14,898,326	0
Conversion of Preferred Stock warrants into Common Stock and Common Stock Warrants			84,676	0
Transfer of instruments to property and equipment from inventory			106,617	0
Fair value of warrants issued with debt classified as a liability			176,813	0
Final payment fee due in connection with the repayment of debt classified within other long-term liabilities			$ 400,000	$ 0

Organization and Basis of Prese

Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Basis of Presentation	1. Organization and Basis of Presentation Description of Business Bionano Genomics, Inc. (the “Company”) formed in January 2003 as BioNanomatrix LLC, a Delaware limited liability company. In August 2007, the Company became BioNanomatrix Inc., a Delaware corporation. In October 2011, the Company changed its name to BioNano Genomics, Inc., and in July 2018, it changed its name to Bionano Genomics, Inc. The Company is a life sciences instrumentation company in the genome analysis space. The Company currently develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Initial Public Offering In August 2018, the Company completed its initial public offering (the “IPO”), in which it sold an aggregate of 3,864,000 units (each unit consisting of one share of the Company’s common stock and one warrant to purchase one share of the Company’s common stock) at a public offering price of $6.125 per unit, which included the sale of 504,000 units pursuant to the exercise of the underwriters’ over-allotment option. The Company received net cash proceeds of $19.4 million, after deducting underwriters' discounts and commissions of $2.2 million and other offering expenses of $2.1 million. In addition, each of the following occurred in connection with the completion of the IPO in August 2018: • The conversion of all outstanding shares of convertible preferred stock into an aggregate 2,850,280 shares of common stock. • The automatic adjustment of preferred stock warrants into common stock warrants; the entire $84,676 balance of preferred stock warrant liability was reclassified as additional paid-in-capital. In addition, the Company issued warrants to the IPO underwriters to purchase up to 115,920 shares of its common stock at fair value of $0.4 million. • The conversion of an aggregate of $14.9 million of outstanding convertible promissory notes and accrued interest into an aggregate of 3,239,294 shares of common stock. Each unit offered in the IPO consisted of one share of common stock and one warrant to purchase one share common stock. Each warrant to purchase common stock contained in the unit entitled the holder to purchase one share of common stock at an initial exercise price of $6.125 per share (100% of the offering price per unit), subject to adjustment. The warrants and shares of common stock traded together as units for 30 days following the IPO. After 30 days of trading, the units automatically separated and the common stock and warrants began trading separately. The units, common stock, and warrants are listed on the Nasdaq Stock Market LLC under the symbols “BNGOU,” “BNGO” and “BNGOW,” respectively. Reverse Stock Splits On July 16, 2018, the Company effected a one-for-21.4 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company’s redeemable convertible preferred stock, and on August 15, 2018, the Company effected an additional one-for-two reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company’s redeemable conversion Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). Therefore, these unaudited condensed consolidated interim financial statements should be read in conjunction with the Company’s audited consolidated financial statements and footnotes thereto as of and for the year ended December 31, 2017 included in the Company’s final prospectus dated August 21, 2018 included in its Registration Statement on Form S-1 (File No. 333-225970), as filed with the Securities and Exchange Commission pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended. The unaudited interim condensed consolidated financial statements included in this report have been prepared on the same basis as the Company's audited consolidated financial statements and include all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations, cash flows, and statement of convertible preferred stock and stockholders' deficit for the periods presented. The condensed consolidated balance sheet as of December 31, 2017, presented herein, has been derived from the Company’s audited consolidated financial statements as of and for the year-ended December 31, 2017. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expense, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. In the accompanying condensed consolidated statements of operations, subtotal categories for cost of revenue and operating expenses have been inserted.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Accounts Receivable The Company extends credit to its customers in the normal course of business based upon an evaluation of each customer’s credit history, financial condition, and other factors. Estimates of allowances for doubtful accounts are determined by evaluating individual customer circumstances, historical payment patterns, length of time past due, and economic and other factors. Bad debt expense is recorded as necessary to maintain an appropriate level of allowance for doubtful accounts in selling, general and administrative expense. The following table reflects the activity related to the Company’s allowance for doubtful accounts: September 30, 2018 December 31, 2017 Accounts receivable $ 4,000,924 $ 3,614,214 Provision — (262,000 ) Accounts receivable, net $ 4,000,924 $ 3,352,214 For the nine months ended September 30, 2018 and the year ended December 31, 2017, Ultravision Technology Ltd. represented 16% and 21% and BioStar Company represented 0% and 15%, respectively, of the Company’s accounts receivable balance. Inventory Inventory is stated at the lower of cost or net realizable value, on a first-in, first-out basis. Inventory includes raw materials and finished goods that may be used in the research and development process and such items are expensed as consumed or expired. Provisions for slow-moving, excess, and obsolete inventories are estimated based on product life cycles, historical experience, and usage forecasts. The components of inventories are as follows (unaudited): September 30, 2018 December 31, 2017 Materials and supplies $ 242,783 $ 203,085 Finished Goods 2,372,029 1,490,657 Total $ 2,614,812 $ 1,693,742 During the year ended December 31, 2017, in connection with the market launch of the Company’s next generation product, the Saphyr system, the Company determined that its first generation Irys instruments on hand had net realizable values below carrying value. Accordingly, the Company recorded a charge of $0.4 million included in cost of product revenue to write-down these instruments to net realizable value of $1.3 million. A fter considering the weight of evidence that accumulated during the three months ended September 2018, including Revenue Recognition Product Revenue Product revenue represents the sale of the Company’s instruments and consumables to third parties. Timing of revenue recognition on instrument sales is based upon when delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. The majority of the Company’s instruments contain embedded operating systems and other software which is included in the purchase price of the instrument. The software is deemed incidental to the system as a whole as it is not sold or marketed separately and its production costs are minor compared to those of the hardware system. Hardware and software elements are both delivered when ownership is transferred to the customer. Hardware upgrades, which are made available to customers for purchase, are recognized as revenue when delivered and all revenue recognition criteria noted above have been met. Installation services for direct sale customers are performed at the same time or shortly after the product is delivered and require only a minimal effort to complete. The Company believes installation is a perfunctory service and is not material to its obligations in the contract. Other Revenue Other revenue includes revenue from extended service contracts and other services that may be performed. Revenue for extended warranty contracts is recognized ratably over the service period. Revenue for other services is generally recognized based on proportional performance of the contract, when the Company’s ability to complete project requirements is reasonably assured. Deferred revenue represents amounts received in advance for on-going service arrangements. Most of these services are completed in a short period of time from the receipt of the customer’s order. When significant risk exists in the Company’s ability to fulfill project requirements, revenue is recognized upon completion of the contract. Multiple Element Arrangements The Company regularly enters into contracts where revenue is derived from multiple deliverables, including products or services. These contracts typically include an instrument, consumables, and extended service contracts. Revenue recognition for contracts with multiple deliverables is based on the individual units of accounting determined to exist in the contract. A delivered item is considered a separate unit of accounting when the delivered item has value to the customer on a stand-alone basis. Items are considered to have stand-alone value when they are sold separately by any vendor or when the customer could resell the item on a stand-alone basis. For transactions with multiple deliverables, consideration is allocated at the inception of the contract to all deliverables based on their relative selling price. The relative selling price for each deliverable is determined using vendor-specific objective evidence (“VSOE”) of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence exists, the Company uses its best estimate of the selling price using average selling prices over an appropriate period coupled with an assessment of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company considers its approved standard prices adjusted for applicable discounts. In order to establish VSOE of selling price, the Company must regularly sell the product or service on a standalone basis with a substantial majority priced within a relatively narrow range. In cases where there is not a sufficient number of standalone sales and VSOE of selling price cannot be determined, then the Company utilizes third-party evidence to establish selling price. Distributor Transactions In certain markets, the Company sells products and provides services to customers through distributors that specialize in life sciences products. In cases where the product is delivered to a distributor, revenue recognition generally occurs when title transfers to the distributor. The terms of sales transactions through distributors are generally consistent with the terms of direct sales to customers and do not contain return rights. Distributor sales transactions typically differ from direct customer sales as they do not require the Company’s services to install the instrument at the end customer or perform the services for the customer that are beyond the standard warranty in the first year following the sale. These transactions are accounted for in accordance with the Company’s revenue recognition policy described herein. Offering Costs The offering costs associated with the IPO consist of legal, accounting and filing fees. The Company had $4,659,369 of IPO costs as of September 30, 2018. These costs have been recorded as a reduction of the gross proceeds from the IPO in stockholder’s equity . Convertible Preferred Stock Warrants The Company previously accounted for outstanding warrants to purchase shares of convertible preferred stock as liabilities in the balance sheets under preferred stock warrant liability. The convertible preferred stock warrants were subject to remeasurement at each reporting period, with changes in fair value recorded as change in fair value of warrants and expirations in the condensed consolidated statements of operations. In connection with the IPO, all outstanding warrants previously exercisable for shares of preferred stock either expired or were adjusted to exercisable for shares of common stock. As of September 30, 2018, there were no outstanding warrants to purchase shares of convertible preferred stock due to this adjustment. Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker, the Chief Executive Officer, views the Company’s operations and manages its business in one operating segment. Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company’s potentially dilutive securities which include outstanding stock options under the Company’s equity incentive plan have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares) (unaudited): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Common Stock Options 415,137 420,678 415,137 420,678 Warrants 4,015,013 855,206 4,015,013 855,206 Total 4,430,150 1,275,884 4,430,150 1,275,884 Recent Accounting Pronouncements On April 5, 2012, the Jump-Start Our Business Startups Act (the “JOBS Act”) was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an emerging growth company. As an emerging growth company, the Company may elect to adopt new or revised accounting standards when they become effective for non-public companies, which typically is later than when public companies must adopt the standards. The Company has elected to take advantage of the extended transition period afforded by the JOBS Act and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for emerging growth companies, which are the dates included below. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). In February 2015, the FASB issued ASU 2016-02, Leases (Topic 842) Leases (Topic 842): Targeted Improvements In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities (ASU 2016-01) In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments (Topic 230)

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability. Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). Fair Value Measurement Using September 30, Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs 2018 Level 1 Level 2 Level 3 Assets Cash and cash equivalents $ 20,657,038 $ 20,657,038 $ — $ — Total assets $ 20,657,038 $ 20,657,038 $ — $ — Liabilities Preferred stock warrant liability $ — $ — $ — $ — Total liabilities $ — $ — $ — $ — Fair Value Measurements Using December 31, Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs 2017 Level 1 Level 2 Level 3 Assets Cash and cash equivalents $ 1,021,897 $ 1,021,897 $ — $ — Total assets $ 1,021,897 $ 1,021,897 $ — $ — Liabilities Preferred stock warrant liability $ 3,898,944 $ — $ — $ 3,898,944 Total liabilities $ 3,898,944 $ — $ — $ 3,898,944 As discussed in Note 2 above, there were no warrants exercisable for the Company’s convertible preferred stock following the closing of the IPO. Of the 37.2 million warrants previously exercisable for preferred stock, 35.7 million warrants expired on the effective date of the IPO. The remaining 1.5 million warrants previously exercisable for preferred stock were adjusted to become exercisable for common stock. Prior to the IPO, the Company estimated fair value of the convertible preferred stock warrants at the time of issuance and subsequent remeasurement using the Black-Scholes-Merton model at each reporting date. On the date of the IPO and going forward, all outstanding warrants are accounted for as equity and are not subject to remeasurement. Estimating fair values of derivative financial instruments, including Level 3 instruments, require the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors, including changes in the estimated fair value of the Company’s equity securities. The following table summarizes the changes in fair value of the Company’s Level 3 liabilities for the year ended December 31, 2017, and the nine months ended September 30, 2018: Warrant Liability Balance at January 1, 2017 $ 4,650,877 Expiration of Series A warrants (1,424 ) Change in fair value of preferred stock warrants (750,509 ) Balance at December 31, 2017 3,898,944 Issuance of warrants in connection with debt (unaudited) 176,813 Change in fair value of preferred stock warrants (unaudited) (3,991,081 ) Conversion of preferred stock warrants to common stock warrants due to IPO (unaudited) (84,676 ) Balance at September 30, 2018 (unaudited) $ — The warrants to purchase convertible preferred stock were valued at each reporting period using the Black-Scholes-Merton model. This valuation includes observable inputs such as risk-free rate, as well as unobservable inputs for assumed volatility, the expected life of the warrants, and the fair value of the underlying convertible preferred stock. Quantitative information relating to unobservable inputs is disclosed below: December 31, 2017 Risk-free interest rate 1.75 % Volatility 54.60 % Expected life (in years) 0.6 Dividend Yield — Fair value of Series A preferred stock $ 0.66 Fair value of Series B-1 preferred stock $ 0.36 Fair value of Series D preferred stock $ 0.48 Fair value of Series D-1 preferred stock $ 0.48

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2018
Prepaid Expense And Other Assets Current [Abstract]
Prepaid Expenses And Other Current Assets	4. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following: September 30, 2018 December 31, 2017 Prepayment to supplier $ 249,071 $ 492,330 Other current assets 1,098,703 579,182 Total $ 1,347,774 $ 1,071,512

Property and Equipment, net

Property and Equipment, net	9 Months Ended
	Sep. 30, 2018
Property Plant And Equipment [Abstract]
Property and Equipment, net	5. Property and Equipment, net Property and equipment, net consist of the following: September 30, 2018 December 31, 2017 Computer and office equipment $ 476,402 $ 476,402 Lab equipment 4,156,519 3,995,731 Service equipment placed at customer sites 594,553 594,553 Leasehold improvements 1,860,667 1,860,667 7,088,141 6,927,353 Less accumulated depreciation and amortization (5,038,885 ) (3,921,565 ) $ 2,049,256 $ 3,005,788 The Company recorded depreciation and amortization expense of $391,246 and $240,551 for the three months ended September 30, 2018 and 2017, and $1,169,801 and $964,932 for the nine months ended September 30, 2018 and 2017, respectively in operating expenses.

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2018
Accrued Liabilities Current [Abstract]
Accrued Expenses	6. Accrued Expenses Accrued expenses consist of the following: September 30, 2018 December 31, 2017 Accrued expenses $ 2,185,354 $ 2,596,137 Accrued bonus 629,936 912,757 Total $ 2,815,290 $ 3,508,894

Long-Term Debt

Long-Term Debt	9 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Long-Term Debt	7. Long-Term Debt Western Alliance LSA On March 8, 2016, the Company entered into a new term Loan and Security Agreement with Western Alliance Bank (the “Western Alliance LSA”) for $7.0 million. The loan proceeds were used to repay the outstanding $5.0 million loan with Square 1 Bank, as required by the twelfth amendment to the Loan and Security Agreement with Square 1 Bank. The Company paid debt issuance costs and a facility fee totaling $113,542 at the inception of the loan, which was recorded as a debt discount and was being recognized as additional interest expense over the term of the loan. In addition, upon repayment of the total amounts borrowed, the Company was required to pay an end of term charge equal to 3.25% of the total amount borrowed. Accordingly, an end of term charge of $227,500 was recorded as debt discount and was included on the balance sheet under current liabilities as December 31, 2017. The end of term charge was being recognized as additional interest expense over the term of the loan. Additionally, in conjunction with the entry into Western Alliance LSA, the Company issued to Western Alliance Bank a warrant to purchase 510,417 shares of Series D convertible preferred stock at an exercise price of $0.48 per share. The Company valued the warrant to purchase Series D convertible preferred stock using the Black-Scholes-Merton model, and the initial fair value of the warrant to purchase Series D convertible preferred stock of $65,384 was recorded as a debt discount and was being amortized to interest expense over the term of the loan. Upon the closing of the IPO in August 2018, the warrants exercisable for shares of Series D convertible preferred stock were adjusted to warrants exercisable for 11,925 shares of common stock for $20.54 per share. The warrants expire on March 8, 2026. On December 9, 2016, the Western Alliance LSA was amended, in conjunction with this amendment, the Company issued to Western Alliance Bank a warrant to purchase 291,667 shares of Series D-1 convertible preferred stock. The Company valued the warrant to purchase Series D-1 convertible preferred stock using the Black-Scholes-Merton model, and the initial fair value of the warrant to purchase Series D-1 convertible preferred stock of $34,300 was recorded as a debt discount and was being amortized to interest expense over the term of the loan. Upon the closing of the IPO in August 2018, the warrants exercisable for shares of Series D convertible preferred stock were adjusted to warrants exercisable for 6,814 shares of common stock for $20.55 per share. The warrants expire on Dec 9, 2026. On November 20, 2017, the Western Alliance LSA was amended, in conjunction with this amendment, the Company agreed to pay an amendment fee of $17,500, which was payable on the earliest to occur of the loan maturity date or the prepayment date. The amount was recorded as a debt discount on the balance sheet and was being recognized as additional interest expense over the remaining term of the loan. The Company received a notice of default from Western Alliance Bank notifying the Company that as of December 31, 2017 it was in default, as it had failed to secure at least $15.0 million from the sale or issuance of its equity securities or subordinated debt as set forth in the amended Western Alliance LSA. Based on the notice of default the Company reclassified the total loan balance of $6.7 million to current liabilities on the consolidated balance sheet as of December 31, 2017, as the loan could be called at any time by Western Alliance Bank. In February 2018, the Western Alliance LSA was amended requiring the Company to secure $21,000,000 in funding prior to June 30, 2018. As part of the amendment, Western Alliance Bank agreed to forbear from exercising any of its default remedies set forth in the Western Alliance LSA as a result of the Company’s loan default. On June 13, 2018, the Western Alliance LSA was amended, replacing previously amended funding requirements and requiring the Company to secure $5.0 million in funding prior to August 3, 2018. Additionally, the amendment restricted Company use of all cash collected from customers, received on and after amendment date, until collecting a total of $2.5 million. As part of the amendment, Western Alliance Back waived the existing default. One June 29, 2018, the Company repaid the Western Alliance LSA as part of the MidCap Financial Credit and Security Agreement discussed below. MidCap Financial CSA On June 29, 2018, the Company entered into a Credit and Security Agreement (CSA) with MidCap Financial Trust which provides a $15.0 million term loan facility available in three tranches, Tranche 1: $10.0 million, Tranche 2: $2.5 million, and Tranche 3: $2.5 million. The Company borrowed $10.0 million from Tranche 1 immediately upon closing the agreement; Tranches 2 and 3 are available to draw from after achieving $12.5 million and $16.0 million in trailing twelve month revenue, respectively. Proceeds from the loan were used to repay the outstanding $7.0 million due to Western Alliance LSA. The MidCap Financial CSA bears interest at an annual rate of one month LIBOR plus 7.5%, subject to a LIBOR floor of 1.5%. The loan has a 60-month term, with interest only for the first 18 months and straight-line amortization of principal and interest for the remaining 42 months. The Company paid issuance fees of approximately $0.3 million at the inception of the loan, which was recorded as a debt discount and is being recognized as additional interest expense over the term of the loan. Subject to certain limited exceptions, amounts prepaid in relation to the MidCap Financial CSA are subject to a prepayment fee determined by multiplying the amount being prepaid by 4% in the first year of the term, 3% in year two, and 2% thereafter. In addition, upon repayment of the total amounts borrowed, the Company will be required to pay an end of term charge equal to 4% of the total amount borrowed. Accordingly, an end of term charge of $0.4 million was recorded as debt discount and is included in other long-term liabilities on the balance sheet as of September 30, 2018. The end of term charge is being recognized as additional interest expense over the term of the loan. In conjunction with entering into the MidCap Financial CSA, the Company issued to MidCap a warrant to purchase 625,000 shares of Series D-1 convertible preferred stock at an exercise price of $0.48 per share that was immediately exercisable and expires June 29, 2028. The Company valued the warrant to purchase Series D convertible preferred stock using the Black-Scholes-Merton model, and the initial fair value of the warrant to purchase Series D-1 convertible preferred stock of $0.2 million was recorded as a debt discount and is being amortized to interest expense over the term of the loan. The assumptions used in the model were: the fair value of the Series D-1 convertible preferred stock, which was determined using an OPM analysis (see Note 3), an expected life of 10 years, a risk-free interest rate of 2.83% and an expected volatility of 59%. Upon the closing of the IPO in August 2018, the warrants exercisable for shares of Series D convertible preferred stock were adjusted to warrants exercisable for 14,603 shares of common stock for $20.55. The warrants expire on June 29, 2028. In addition, MidCap invested $1.0 million in the convertible note offering at terms identical to other investors described in the Convertible Notes section below. Convertible Notes On February 9, 2018, the Company entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with various investors, which included related parties (the “Investors”), pursuant to which the Company agreed to sell to the Investors convertible promissory notes (the “Convertible Notes”) in the original principal amount of up to $16.0 million. On April 2, 2018, the Company amended the Note Purchase Agreement to, among other things, increase the principal amount available for issuance under the Note Purchase Agreement to $18.4 million. The Convertible Notes had a maturity date of September 30, 2018 and were convertible either into the Company’s common stock or convertible preferred stock, dependent on the conversion events. On June 29, 2018, the Note Purchase Agreement was amended to increase the principal amount available for issuance from $18.4 million to $19.4 million. In August 2018, the outstanding convertible promissory notes of $14.9 million of principal and interest were converted into 3,239,294 shares of common stock upon completion of the IPO. As of September 30, 2018, there are no convertible notes outstanding. Debt and unamortized discount balances relating to the Western Alliance LSA are as follows: December 31, 2017 Term loan face value $ 7,000,000 Fair value of warrant (99,684 ) End of term charge (227,500 ) Capitalized debt issuance costs (131,042 ) Accretion of debt issuance costs and end of term charge 148,225 Accretion of warrant fair value 39,753 Balance 6,729,752 Less current portion 6,729,752 Long-term debt $ — Debt and unamortized discount balances relating to the MidCap Financial CSA are as follows: September 30, 2018 Term loan face value $ 10,000,000 Fair value of warrant (176,813 ) End of term charge (400,000 ) Capitalized debt issuance costs (467,044 ) Accretion of debt issuance costs and end of term charge 43,352 Accretion of warrant fair value 8,842 Balance 9,008,337 Less current portion — Long-term debt $ 9,008,337 Non-cash interest expense related to debt discount amortization and accretion of end of term fees was $52,194 and $21,558, for the three months ended September 30, 2018 and 2017 and $121,984 and $66,241 for the nine months ended September 30, 2018 and 2017, respectively. Future minimum payments including interest under the MidCap Financial CSA are as follows as of September 30, 2018: Years ending December 31, 2018 $ 243,900 2019 975,600 2020 3,704,986 2021 3,426,243 2022-2023 5,016,721 Total minimum loan payments $ 13,367,450 Unamortized interest (2,967,450 ) End of term charge (400,000 ) Warrant fair value (167,972 ) Capitalized debt issuance costs and end of term charge (823,691 ) Term loan 9,008,337 Less current portion — Long-term debt $ 9,008,337

Stockholders' Deficit

Stockholders' Deficit	9 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Stockholders’ Deficit	8. Stockholders’ Deficit Common Stock On August 23, 2018, the Company amended and restated its Certificate of Incorporation in connection with the IPO. The Company’s Amended and Restated Certificate of Incorporation authorizes 200,000,000 shares of common stock, During the three months ended September 30, 2018 and 2017, the company issued 1,068 and 1,168 shares of common stock in connection with the exercise of stock options for net proceeds of $1,116 and $1,500, respectively. During the nine months ended September 30, 2018 and 2017, the company issued 1,856 and 1,168 shares of common stock in connection with the exercise of stock options for net proceeds of $3,499 and $1,500, respectively. Convertible Preferred Stock Conversion of all outstanding Preferred Stock to Common Stock In August 2018, due to completion of a public offering meeting certain requires (as defined below), each 42.8 shares of Series Preferred was converted into one share of common stock at a Conversion Price of $1.3995 for each share of Series A, B and B-1 convertible preferred stock, $1.4043 for each share of Series C convertible preferred stock and $0.48 for each share of Series D and D-1 convertible preferred stock. Prior to the August 2018 offering, there were 121,992,497 shares of convertible preferred stock outstanding. The Company’s convertible preferred stock had been classified as temporary equity on the accompanying balance sheets in accordance with authoritative guidance for the classification and measurement of redeemable securities. As of September 30, 2018, there are no shares of convertible preferred stock outstanding. The following sets forth information regarding all convertible preferred stock securities sold since January 1, 2017: Series D-1 Convertible Preferred Stock Financing From February through November 2017, the Company sold and issued 36,974,586 shares of Series D-1 convertible preferred stock at $0.48 per share, raising approximately $17,750,000, net of issuance costs of $154,191. At any time after December 31, 2021, holders of a majority of the then outstanding Series D-1 convertible preferred stock may redeem any unconverted or unredeemed Series D-1 convertible preferred stock in cash at the greater of the original convertible preferred stock purchase price plus all declared but unpaid dividends or the fair market value. The Company had determined not to adjust the carrying values of the Series D-1 convertible preferred stock to the liquidation preferences of such shares because of the uncertainty over whether or when such an event would occur. The Company had determined that it was not probable that such redemption would occur as a mandatory conversion event, the close of the public offering, was expected in advance of the redemption triggers. Convertible Preferred Stock The Series A, B, B-1, C, D and D-1 convertible preferred stock (collectively, the “Series Preferred”) had the following rights and privileges immediately prior to conversion to common stock in connection with the public offering: Voting rights Series Preferred stockholders were entitled to cast the number of votes equal to the number of whole shares of common stock into which the convertible preferred stock was convertible. Conversion Each 42.8 shares of Series Preferred was convertible, at any time, into one share of common stock at the then-applicable Conversion Price (as defined below). The Series Preferred was automatically converted into common stock, at the then-applicable Conversion Price, upon (a) the vote or consent of 66-2/3% of the outstanding shares of Series Preferred or (b) upon the closing of the sale to the public of either shares of common stock or units comprised of shares of common stock and warrants to purchase shares of common stock (i) in which the price per share paid by the public (prior to the deduction of underwriting discounts and registration expenses) was no less than $6.00 per share, or to the extent units are sold in such offering, no less than $6.00 per unit (in each case as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to shares of common stock effectuated after August 15, 2018), in each case in the initial closing of the such offering, and (ii) resulting in at least $15,000,000 in gross proceeds to the company (prior to the deduction of underwriting discounts and registration expenses), in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended. The Conversion Price was initially $1.3995 for each share of Series A, B and B-1 convertible preferred stock, $1.4043 for each share of Series C convertible preferred stock and $0.48 for each share of Series D and D-1 convertible preferred stock. The Conversion Price was subject to adjustment in certain circumstances. Dividends Holders of the Series Preferred were entitled to receive cash dividends at the rate of 8% of the applicable Original Issue Price (as defined below) per annum, on a non-cumulative basis, on each outstanding share of Series Preferred. The Company could not declare any dividends on any shares of Series Preferred other than shares of Series D-1 convertible preferred stock unless the holders of the Series D-1 convertible preferred stock then outstanding first receive, or simultaneously receive, full payment of a dividend. The Original Issue Price was $2.733 per share for the Series A convertible preferred stock, $1.3995 per share for the Series B convertible preferred stock, $1.3995 per share for the Series B-1 convertible preferred stock, $1.4043 per share for the Series C convertible preferred stock, $0.48 per share for the Series D convertible preferred stock and $0.48 per share for the Series D-1 convertible preferred stock, each subject to adjustment in the event of any reorganization, stock split, recapitalization or other similar event involving or affecting a change in the Company’s capital structure. Liquidation Preferences In the event of liquidation or winding up of the Company, (i) the holders of the Series D and D-1 convertible preferred stock, on a pari passu basis, were entitled to receive, prior to and in preference to any payment or distribution to the holders of, Series C convertible preferred stock, Series B and B-1 convertible preferred stock, Series A convertible preferred stock and common stock, a per-share amount equal to the applicable Liquidation Preference (as defined below); (ii) the holders of the Series C convertible preferred stock, on a pari passu basis, were entitled to receive, prior to and in preference to any payment or distribution to the holders of Series B and B-1 convertible preferred stock, Series A convertible preferred stock, and common stock, a per-share amount equal to the applicable Liquidation Preference; and (iii) the holders of Series B and B-1 convertible preferred stock and the holders of Series A convertible preferred stock, on a pari passu basis, were entitled to receive, prior to and in preference to any payment or distribution to the holders of common stock, a per-share amount equal to the applicable Liquidation Preference. The Liquidation Preference was calculated as follows: (i) when the Company was valued at $91 million or below, the Liquidation Preference was equal to the applicable Original Issue Price for such shares plus the amount of any declared but unpaid dividends and (ii) when the company was valued greater than $91 million, the Liquidation Preference was equal to the applicable Original Issue Price for such shares plus the amount of any declared but unpaid dividends, with the first $10 million of proceeds above $91 million distributed to the holders of the Series D and D-1 convertible preferred stock on a pro rata basis ((i) and (ii) together, “Liquidation Preference”). Stock Options In August 2018, the Company’s board of directors (the “Board”) and its stockholders adopted the 2018 Equity Incentive Plan (the “2018 Plan”), as a successor to and continuation of the Company’s 2006 Equity Incentive Plan (the “2006 Plan”). Under the 2018 Plan the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then its employees, directors and consultants, including employees and consultants of its affiliates. The Company has initially reserved 1,499,454 shares of common stock for issuance under the 2018 Plan, which is the sum of (1) 1,000,000 new shares, plus (2) the number of shares that remained available for issuance under the 2006 Plan at the time the 2018 Plan became effective, and (3) any shares subject to outstanding stock options or other stock awards that were granted under the 2006 Plan that would have otherwise returned to the 2006 Plan. In addition, the number of shares of common stock reserved for issuance under the 2018 Plan will automatically increase on January 1 of each calendar year, starting on January 1, 2019 through January 1, 2028, in an amount equal to 5% of the total number of shares of the Company’s capital stock outstanding on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by the Board. As of September 30, 2018, there were 415,137 shares of common stock subject to outstanding options and 1,084,285 shares of common stock reserved for future stock awards under the 2018 Plan. A summary of the Company’s stock option activity under the 2018 Plan and 2006 Plan is as follows: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2018 436,341 $ 5.14 9.0 $ — Granted (unaudited) 385 6.00 — Exercised (unaudited) (1,856 ) 1.28 $ 4,571 Cancelled/Expired (unaudited) (19,733 ) 9.65 — Outstanding at September 30, 2018 (unaudited) 415,137 $ 4.99 8.2 $ 2,589,204 Vested and expected to vest at September 30, 2018 (unaudited) 399,705 $ 5.14 8.2 $ 2,487,288 Vested and exercisable at September 30, 2018 (unaudited) 261,487 $ 6.73 8.1 $ 1,580,698 For the three months ended September 30, 2018 and 2017, the Company granted to its employee’s options to purchase no shares and 17,769 shares of its common stock with an exercise price of $1.28 per share, respectively. For the nine months ended September 30, 2018 and 2017, the Company granted to its employee’s options to purchase 385 shares and 422,706 shares of its common stock with an exercise price of $6.00 per share and $1.28 per share, respectively. For the three months ended September 30, 2018 and 2017, the total grant date fair value of vested options was $50,584 and $60,515, respectively. The Company did not grant employee options during the three months ended September 30, 2018; the weighted-average grant date fair value of employee option grants during the three months ended September 30, 2017 was $0.67. For the nine months ended September 30, 2018 and 2017, the total grant date fair value of vested options was $161,897 and $232,915, respectively. The weighted-average grant date fair value of employee option grants during the nine months ended September 30, 2018 and 2017 was $2.99 and $0.66, respectively. Stock-Based Compensation Expense The Company recognized stock-based compensation expense of Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Research and development $ 43,363 $ 18,564 $ 131,900 $ 162,420 General and administrative 9,762 5,561 28,651 79,551 Total stock-based compensation expense $ 53,125 $ 24,125 $ 160,551 $ 241,971 The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Risk-free interest rate — 1.8 % 2.5 % 2.5 % Expected volatility — 58.0 % 63.0 % 58.0 % Expected term (in years) — 5.3 4.0 5.1 - 5.3 Expected dividend yield — 0.0 % 0.0 % 0.0 % Risk-free interest rate. The risk-free rate assumption is based on the U.S. Treasury instruments, the terms of which were consistent with the expected term of the Company’s stock options. Expected volatility. Due to the Company’s limited operating history and lack of company-specific historical or implied volatility as a private company, the expected volatility assumption was determined by examining the historical volatilities of a group of industry peers whose share prices are publicly available. Expected term. The expected term of stock options represents the weighted-average period the stock options are expected to be outstanding. The Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded. As a result, the Company uses the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual life of the options. Expected dividend yield. The expected dividend assumption is based on the Company’s history and expectation of dividend payouts. The Company has not paid and does not intend to pay dividends. Forfeitures . The Company reduces stock-based compensation expense for actual forfeitures during the period. As of September 30, 2018 the unrecognized compensation cost related to outstanding employee options was $132,726 and is expected to be recognized as expense over approximately 1.1 years. Employee Stock Purchase Plan In August 2018, the Board and the Company’s stockholders adopted the 2018 Employee Stock Purchase Plan (the “ESPP”). A total of 175,000 shares of common stock are initially reserved for issuance under the ESPP. In addition, the number shares of common stock reserved for issuance under the ESPP will automatically increase each on January 1 of each calendar year, beginning on January 1, 2019, through January 1, 2028, by the lesser of (1) 1% of the total number of shares of the Company’s common stock outstanding on the last day of the calendar month before the date of the automatic increase, (2) 220,000 shares, or (3) a lesser number of shares as determined by the Board. As of September 30, 2018, no shares of common stock have been purchased under the ESPP. Common Stock Reserved for Future Issuance Common stock reserved for future issuance consist of the following: Nine Months Ended September 30, 2018 Stock options issued and outstanding 415,137 Authorized for future stock awards, option grants, or employee stock purchase program 1,259,285 Common Warrants 4,015,013 Total 5,689,435

Commitment and Contingencies

Commitment and Contingencies	9 Months Ended
	Sep. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies Leases The Company leases certain office and lab space in San Diego, California under a non-cancelable operating lease, which was amended July 1, 2015 to add laboratory space and office space and extend its terms through December 2020. Rent expense for the three months ended September 30, 2018 and 2017 was $147,522 each period, including the offset for amortization of leasehold incentive obligation of $56,263 each period. Rent expense for the nine months ended September 30, 2018 and 2017 was $442,566 each period, including the offset for amortization of leasehold incentive obligation of The future minimum lease payments required under non-cancelable leases as of September 30, 2018, are summarized as follows: Year Ending December 31, 2018 (3 months remaining) $ 206,721 2019 862,656 2020 902,412 Total minimum lease payments $ 1,971,789 Royalty Agreements The Company has entered into agreements to market and distribute chips and kits used in its instruments. Pursuant to these agreements, the Company is obligated to pay royalties based on sales during each annual license period and is obligated to make minimum payments regardless of the level of sales achieved. The Company has paid $76,846 and $75,960 for the three months ended September 30, 2018 and 2017, and $295,246 and $235,455 for the nine months ended September 30, 2018 and 2017, respectively. Such royalty agreements extend through the life of underlying intellectual property which is affected by patent filing date and jurisdiction. As of December 31, 2017, annual future minimum royalty payments under the Company’s royalty agreements total $70,000, on a continuing basis, and extend through November 29, 2026. Purchase Commitments The Company has a contractual commitment with a supplier to purchase $100,000 of products each quarter until the first quarter of 2019. The Company is not able to determine the aggregate amount of other such purchase orders that represent contractual obligations, as purchase orders may represent authorizations to purchase rather than binding agreements. The Company’s purchase orders are based on its current procurement or development needs and are fulfilled by the Company’s vendors within short time horizons. Litigation The Company is subject to potential liabilities under various claims and legal actions that are pending or may be asserted. These matters arise in the ordinary course and conduct of the business. The Company intends to continue to defend itself vigorously in such matters. The Company regularly assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in the financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Based on the Company’s assessment, it currently does not have any amount accrued as it is not a defendant in any claims or legal actions.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes The Company is subject to taxation in the United States, United Kingdom and various state jurisdictions. The Company computes its quarterly income tax provision by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. The primary difference between the effective tax rate and the federal statutory tax rate relates to the full valuation allowance on the Company's U.S. net operating losses. At September 30, 2018 and 2017, respectively the provision for income taxes reflected on the statements of operations reflect an effective tax rate of -0.06% and -0.10% respectively. Federal, state, and foreign income tax expense/(benefit) was $(2,978) and $(4,738) for the three months ended September 30, 2018, and 2017 respectively; and $6,304 and $17,620 for the nine months ended September 30, 2018 and 2017, respectively. As of September 30, 2018 and 2017, management assessed the realizability of deferred tax assets and evaluated the need for a valuation allowance on deferred tax assets on a jurisdictional basis. This evaluation utilizes the framework contained in ASC 740, Income Taxes, wherein management analyzes all positive and negative evidence available at the balance sheet date to determine whether all or some portion of our deferred tax assets will not be realized. Under this guidance, a valuation allowance must be established for deferred tax assets when it is more likely than not (a probability level of more than 50 percent) that they will not be realized. Because of our history of losses and the uncertainty as to the realization of those deferred tax assets, a full valuation allowance has been recognized for the U.S. federal and state jurisdictions. Utilization of the net operating losses and research and development (“R&D”) credit carryforwards are subject to annual limitations due to ownership change limitations that have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), as well as similar state and foreign provisions. These ownership changes may limit the amount of net operating losses and R&D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an “ownership change” as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders. During 2013, the Company completed a Section 382/383 analysis, from inception through December 31, 2012, regarding the limitation of the net operating losses and R&D credits. Based upon the analysis, the Company determined that no ownership changes occurred during that period. However, there may have been ownership changes subsequent to December 31, 2012, that could limit the Company’s ability to utilize the net operating loss and R&D credit carryforwards. The Company plans to complete an analysis prior to using any of the net operating losses and R&D credits. On December 22, 2017, Staff Accounting Bulletin No. 118 (“SAB 118”) was issued to address the application of GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Cuts and Jobs Act (The “Act”). In accordance with SAB 118, the Company’s provisional determination is that there is no deferred tax benefit or expense with respect to the remeasurement of certain deferred tax assets and liabilities due to the full valuation allowance against net deferred tax assets. The Company did not record any adjustments to this provisional amount during the nine months ended September 30, 2018 and will continue to analyze and refine its calculations related to the remeasurement as the impact of the Act is finalized.

Employee Benefits

Employee Benefits	9 Months Ended
	Sep. 30, 2018
Compensation And Retirement Disclosure [Abstract]
Employee Benefits	11. Employee Benefits The Company has a defined contribution 401(k) plan available to eligible employees. Under the terms of the plan, employees may make voluntary contributions as a percent of compensation, limited to the maximum amount allowable under federal tax regulations. The Company, at its discretion, may make certain contributions to the 401(k) plan. The Company made matching contributions of $78,020 and $97,414, and, $211,185 and $334,988, for the three months ended September 30, 2018 and 2017 and the nine months ended September 30, 2018 and 2017, respectively.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Initial Public Offering	Initial Public Offering In August 2018, the Company completed its initial public offering (the “IPO”), in which it sold an aggregate of 3,864,000 units (each unit consisting of one share of the Company’s common stock and one warrant to purchase one share of the Company’s common stock) at a public offering price of $6.125 per unit, which included the sale of 504,000 units pursuant to the exercise of the underwriters’ over-allotment option. The Company received net cash proceeds of $19.4 million, after deducting underwriters' discounts and commissions of $2.2 million and other offering expenses of $2.1 million. In addition, each of the following occurred in connection with the completion of the IPO in August 2018: • The conversion of all outstanding shares of convertible preferred stock into an aggregate 2,850,280 shares of common stock. • The automatic adjustment of preferred stock warrants into common stock warrants; the entire $84,676 balance of preferred stock warrant liability was reclassified as additional paid-in-capital. In addition, the Company issued warrants to the IPO underwriters to purchase up to 115,920 shares of its common stock at fair value of $0.4 million. • The conversion of an aggregate of $14.9 million of outstanding convertible promissory notes and accrued interest into an aggregate of 3,239,294 shares of common stock. Each unit offered in the IPO consisted of one share of common stock and one warrant to purchase one share common stock. Each warrant to purchase common stock contained in the unit entitled the holder to purchase one share of common stock at an initial exercise price of $6.125 per share (100% of the offering price per unit), subject to adjustment. The warrants and shares of common stock traded together as units for 30 days following the IPO. After 30 days of trading, the units automatically separated and the common stock and warrants began trading separately. The units, common stock, and warrants are listed on the Nasdaq Stock Market LLC under the symbols “BNGOU,” “BNGO” and “BNGOW,” respectively.
Reverse Stock-Splits	Reverse Stock Splits On July 16, 2018, the Company effected a one-for-21.4 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company’s redeemable convertible preferred stock, and on August 15, 2018, the Company effected an additional one-for-two reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company’s redeemable conversion
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). Therefore, these unaudited condensed consolidated interim financial statements should be read in conjunction with the Company’s audited consolidated financial statements and footnotes thereto as of and for the year ended December 31, 2017 included in the Company’s final prospectus dated August 21, 2018 included in its Registration Statement on Form S-1 (File No. 333-225970), as filed with the Securities and Exchange Commission pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended. The unaudited interim condensed consolidated financial statements included in this report have been prepared on the same basis as the Company's audited consolidated financial statements and include all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations, cash flows, and statement of convertible preferred stock and stockholders' deficit for the periods presented. The condensed consolidated balance sheet as of December 31, 2017, presented herein, has been derived from the Company’s audited consolidated financial statements as of and for the year-ended December 31, 2017. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expense, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. In the accompanying condensed consolidated statements of operations, subtotal categories for cost of revenue and operating expenses have been inserted.
Accounts Receivable	Accounts Receivable The Company extends credit to its customers in the normal course of business based upon an evaluation of each customer’s credit history, financial condition, and other factors. Estimates of allowances for doubtful accounts are determined by evaluating individual customer circumstances, historical payment patterns, length of time past due, and economic and other factors. Bad debt expense is recorded as necessary to maintain an appropriate level of allowance for doubtful accounts in selling, general and administrative expense. The following table reflects the activity related to the Company’s allowance for doubtful accounts: September 30, 2018 December 31, 2017 Accounts receivable $ 4,000,924 $ 3,614,214 Provision — (262,000 ) Accounts receivable, net $ 4,000,924 $ 3,352,214 For the nine months ended September 30, 2018 and the year ended December 31, 2017, Ultravision Technology Ltd. represented 16% and 21% and BioStar Company represented 0% and 15%, respectively, of the Company’s accounts receivable balance.
Inventory	Inventory Inventory is stated at the lower of cost or net realizable value, on a first-in, first-out basis. Inventory includes raw materials and finished goods that may be used in the research and development process and such items are expensed as consumed or expired. Provisions for slow-moving, excess, and obsolete inventories are estimated based on product life cycles, historical experience, and usage forecasts. The components of inventories are as follows (unaudited): September 30, 2018 December 31, 2017 Materials and supplies $ 242,783 $ 203,085 Finished Goods 2,372,029 1,490,657 Total $ 2,614,812 $ 1,693,742 During the year ended December 31, 2017, in connection with the market launch of the Company’s next generation product, the Saphyr system, the Company determined that its first generation Irys instruments on hand had net realizable values below carrying value. Accordingly, the Company recorded a charge of $0.4 million included in cost of product revenue to write-down these instruments to net realizable value of $1.3 million. A fter considering the weight of evidence that accumulated during the three months ended September 2018, including
Revenue Recognition	Revenue Recognition Product Revenue Product revenue represents the sale of the Company’s instruments and consumables to third parties. Timing of revenue recognition on instrument sales is based upon when delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. The majority of the Company’s instruments contain embedded operating systems and other software which is included in the purchase price of the instrument. The software is deemed incidental to the system as a whole as it is not sold or marketed separately and its production costs are minor compared to those of the hardware system. Hardware and software elements are both delivered when ownership is transferred to the customer. Hardware upgrades, which are made available to customers for purchase, are recognized as revenue when delivered and all revenue recognition criteria noted above have been met. Installation services for direct sale customers are performed at the same time or shortly after the product is delivered and require only a minimal effort to complete. The Company believes installation is a perfunctory service and is not material to its obligations in the contract. Other Revenue Other revenue includes revenue from extended service contracts and other services that may be performed. Revenue for extended warranty contracts is recognized ratably over the service period. Revenue for other services is generally recognized based on proportional performance of the contract, when the Company’s ability to complete project requirements is reasonably assured. Deferred revenue represents amounts received in advance for on-going service arrangements. Most of these services are completed in a short period of time from the receipt of the customer’s order. When significant risk exists in the Company’s ability to fulfill project requirements, revenue is recognized upon completion of the contract. Multiple Element Arrangements The Company regularly enters into contracts where revenue is derived from multiple deliverables, including products or services. These contracts typically include an instrument, consumables, and extended service contracts. Revenue recognition for contracts with multiple deliverables is based on the individual units of accounting determined to exist in the contract. A delivered item is considered a separate unit of accounting when the delivered item has value to the customer on a stand-alone basis. Items are considered to have stand-alone value when they are sold separately by any vendor or when the customer could resell the item on a stand-alone basis. For transactions with multiple deliverables, consideration is allocated at the inception of the contract to all deliverables based on their relative selling price. The relative selling price for each deliverable is determined using vendor-specific objective evidence (“VSOE”) of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence exists, the Company uses its best estimate of the selling price using average selling prices over an appropriate period coupled with an assessment of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company considers its approved standard prices adjusted for applicable discounts. In order to establish VSOE of selling price, the Company must regularly sell the product or service on a standalone basis with a substantial majority priced within a relatively narrow range. In cases where there is not a sufficient number of standalone sales and VSOE of selling price cannot be determined, then the Company utilizes third-party evidence to establish selling price. Distributor Transactions In certain markets, the Company sells products and provides services to customers through distributors that specialize in life sciences products. In cases where the product is delivered to a distributor, revenue recognition generally occurs when title transfers to the distributor. The terms of sales transactions through distributors are generally consistent with the terms of direct sales to customers and do not contain return rights. Distributor sales transactions typically differ from direct customer sales as they do not require the Company’s services to install the instrument at the end customer or perform the services for the customer that are beyond the standard warranty in the first year following the sale. These transactions are accounted for in accordance with the Company’s revenue recognition policy described herein.
Offering Costs	Offering Costs The offering costs associated with the IPO consist of legal, accounting and filing fees. The Company had $4,659,369 of IPO costs as of September 30, 2018. These costs have been recorded as a reduction of the gross proceeds from the IPO in stockholder’s equity .
Convertible Preferred Stock Warrants	Convertible Preferred Stock Warrants The Company previously accounted for outstanding warrants to purchase shares of convertible preferred stock as liabilities in the balance sheets under preferred stock warrant liability. The convertible preferred stock warrants were subject to remeasurement at each reporting period, with changes in fair value recorded as change in fair value of warrants and expirations in the condensed consolidated statements of operations. In connection with the IPO, all outstanding warrants previously exercisable for shares of preferred stock either expired or were adjusted to exercisable for shares of common stock. As of September 30, 2018, there were no outstanding warrants to purchase shares of convertible preferred stock due to this adjustment.
Segment Reporting	Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker, the Chief Executive Officer, views the Company’s operations and manages its business in one operating segment.
Net Loss Per Share	Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. The Company’s potentially dilutive securities which include outstanding stock options under the Company’s equity incentive plan have been excluded from the computation of diluted net loss per share as they would be anti-dilutive to the net loss per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares) (unaudited): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Common Stock Options 415,137 420,678 415,137 420,678 Warrants 4,015,013 855,206 4,015,013 855,206 Total 4,430,150 1,275,884 4,430,150 1,275,884
Recent Accounting Pronouncements	Recent Accounting Pronouncements On April 5, 2012, the Jump-Start Our Business Startups Act (the “JOBS Act”) was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting requirements for an emerging growth company. As an emerging growth company, the Company may elect to adopt new or revised accounting standards when they become effective for non-public companies, which typically is later than when public companies must adopt the standards. The Company has elected to take advantage of the extended transition period afforded by the JOBS Act and, as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for emerging growth companies, which are the dates included below. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). In February 2015, the FASB issued ASU 2016-02, Leases (Topic 842) Leases (Topic 842): Targeted Improvements In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities (ASU 2016-01) In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments (Topic 230)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Schedule of Allowance for Doubtful Accounts	The following table reflects the activity related to the Company’s allowance for doubtful accounts: September 30, 2018 December 31, 2017 Accounts receivable $ 4,000,924 $ 3,614,214 Provision — (262,000 ) Accounts receivable, net $ 4,000,924 $ 3,352,214
Schedule of Components of Inventories	The components of inventories are as follows (unaudited): September 30, 2018 December 31, 2017 Materials and supplies $ 242,783 $ 203,085 Finished Goods 2,372,029 1,490,657 Total $ 2,614,812 $ 1,693,742
Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders	Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares) (unaudited): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Common Stock Options 415,137 420,678 415,137 420,678 Warrants 4,015,013 855,206 4,015,013 855,206 Total 4,430,150 1,275,884 4,430,150 1,275,884

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Schedule of Fair Value Measurement of Assets And Liabilities	Fair Value Measurement Using September 30, Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs 2018 Level 1 Level 2 Level 3 Assets Cash and cash equivalents $ 20,657,038 $ 20,657,038 $ — $ — Total assets $ 20,657,038 $ 20,657,038 $ — $ — Liabilities Preferred stock warrant liability $ — $ — $ — $ — Total liabilities $ — $ — $ — $ — Fair Value Measurements Using December 31, Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs 2017 Level 1 Level 2 Level 3 Assets Cash and cash equivalents $ 1,021,897 $ 1,021,897 $ — $ — Total assets $ 1,021,897 $ 1,021,897 $ — $ — Liabilities Preferred stock warrant liability $ 3,898,944 $ — $ — $ 3,898,944 Total liabilities $ 3,898,944 $ — $ — $ 3,898,944
Summary of Changes In Level 3 Liabilities	The following table summarizes the changes in fair value of the Company’s Level 3 liabilities for the year ended December 31, 2017, and the nine months ended September 30, 2018: Warrant Liability Balance at January 1, 2017 $ 4,650,877 Expiration of Series A warrants (1,424 ) Change in fair value of preferred stock warrants (750,509 ) Balance at December 31, 2017 3,898,944 Issuance of warrants in connection with debt (unaudited) 176,813 Change in fair value of preferred stock warrants (unaudited) (3,991,081 ) Conversion of preferred stock warrants to common stock warrants due to IPO (unaudited) (84,676 ) Balance at September 30, 2018 (unaudited) $ —
Summary of Quantitative Information Relating to Unobservable Inputs	The warrants to purchase convertible preferred stock were valued at each reporting period using the Black-Scholes-Merton model. This valuation includes observable inputs such as risk-free rate, as well as unobservable inputs for assumed volatility, the expected life of the warrants, and the fair value of the underlying convertible preferred stock. Quantitative information relating to unobservable inputs is disclosed below: December 31, 2017 Risk-free interest rate 1.75 % Volatility 54.60 % Expected life (in years) 0.6 Dividend Yield — Fair value of Series A preferred stock $ 0.66 Fair value of Series B-1 preferred stock $ 0.36 Fair value of Series D preferred stock $ 0.48 Fair value of Series D-1 preferred stock $ 0.48

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2018
Prepaid Expense And Other Assets Current [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following: September 30, 2018 December 31, 2017 Prepayment to supplier $ 249,071 $ 492,330 Other current assets 1,098,703 579,182 Total $ 1,347,774 $ 1,071,512

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	9 Months Ended
	Sep. 30, 2018
Property Plant And Equipment [Abstract]
Schedule of Property and Equipment, net	Property and equipment, net consist of the following: September 30, 2018 December 31, 2017 Computer and office equipment $ 476,402 $ 476,402 Lab equipment 4,156,519 3,995,731 Service equipment placed at customer sites 594,553 594,553 Leasehold improvements 1,860,667 1,860,667 7,088,141 6,927,353 Less accumulated depreciation and amortization (5,038,885 ) (3,921,565 ) $ 2,049,256 $ 3,005,788

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2018
Accrued Liabilities Current [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of the following: September 30, 2018 December 31, 2017 Accrued expenses $ 2,185,354 $ 2,596,137 Accrued bonus 629,936 912,757 Total $ 2,815,290 $ 3,508,894

Long-Term Debt (Tables)

Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2018
Western Alliance LSA
Debt Instrument [Line Items]
Schedule of Debt and Unamortized Discount Balances	Debt and unamortized discount balances relating to the Western Alliance LSA are as follows: December 31, 2017 Term loan face value $ 7,000,000 Fair value of warrant (99,684 ) End of term charge (227,500 ) Capitalized debt issuance costs (131,042 ) Accretion of debt issuance costs and end of term charge 148,225 Accretion of warrant fair value 39,753 Balance 6,729,752 Less current portion 6,729,752 Long-term debt $ —
MidCap Financial CSA
Debt Instrument [Line Items]
Schedule of Debt and Unamortized Discount Balances	Debt and unamortized discount balances relating to the MidCap Financial CSA are as follows: September 30, 2018 Term loan face value $ 10,000,000 Fair value of warrant (176,813 ) End of term charge (400,000 ) Capitalized debt issuance costs (467,044 ) Accretion of debt issuance costs and end of term charge 43,352 Accretion of warrant fair value 8,842 Balance 9,008,337 Less current portion — Long-term debt $ 9,008,337
Schedule of Future Minimum Payments Including Interest	Future minimum payments including interest under the MidCap Financial CSA are as follows as of September 30, 2018: Years ending December 31, 2018 $ 243,900 2019 975,600 2020 3,704,986 2021 3,426,243 2022-2023 5,016,721 Total minimum loan payments $ 13,367,450 Unamortized interest (2,967,450 ) End of term charge (400,000 ) Warrant fair value (167,972 ) Capitalized debt issuance costs and end of term charge (823,691 ) Term loan 9,008,337 Less current portion — Long-term debt $ 9,008,337

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	9 Months Ended
	Sep. 30, 2018
Summary of Recognized Stock-Based Compensation Expense	The Company recognized stock-based compensation expense of Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Research and development $ 43,363 $ 18,564 $ 131,900 $ 162,420 General and administrative 9,762 5,561 28,651 79,551 Total stock-based compensation expense $ 53,125 $ 24,125 $ 160,551 $ 241,971
Schedule of Weighted-Average Assumptions in Black -Scholes Option Pricing Model	The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Risk-free interest rate — 1.8 % 2.5 % 2.5 % Expected volatility — 58.0 % 63.0 % 58.0 % Expected term (in years) — 5.3 4.0 5.1 - 5.3 Expected dividend yield — 0.0 % 0.0 % 0.0 %
Schedule of Common Stock Reserved for Future Issuance	Common stock reserved for future issuance consist of the following: Nine Months Ended September 30, 2018 Stock options issued and outstanding 415,137 Authorized for future stock awards, option grants, or employee stock purchase program 1,259,285 Common Warrants 4,015,013 Total 5,689,435
2018 Plan and 2006 Plan
Summary of Stock Option Activity Under 2018 Plan and 2006 Plan	A summary of the Company’s stock option activity under the 2018 Plan and 2006 Plan is as follows: Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at January 1, 2018 436,341 $ 5.14 9.0 $ — Granted (unaudited) 385 6.00 — Exercised (unaudited) (1,856 ) 1.28 $ 4,571 Cancelled/Expired (unaudited) (19,733 ) 9.65 — Outstanding at September 30, 2018 (unaudited) 415,137 $ 4.99 8.2 $ 2,589,204 Vested and expected to vest at September 30, 2018 (unaudited) 399,705 $ 5.14 8.2 $ 2,487,288 Vested and exercisable at September 30, 2018 (unaudited) 261,487 $ 6.73 8.1 $ 1,580,698

Commitment and Contingencies (T

Commitment and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments Required under Non-Cancelable Leases	The future minimum lease payments required under non-cancelable leases as of September 30, 2018, are summarized as follows: Year Ending December 31, 2018 (3 months remaining) $ 206,721 2019 862,656 2020 902,412 Total minimum lease payments $ 1,971,789

Organization and Basis of Pre_2

Organization and Basis of Presentation - Additional Information (Details) - USD ($)	Aug. 15, 2018	Jul. 16, 2018	Aug. 31, 2018	Sep. 30, 2018	Sep. 30, 2017
Organization And Basis Of Presentation [Line Items]
Conversion of preferred stock warrants into common stock warrants				$ 84,676
Outstanding convertible promissory notes and accrued interest converted, amount				$ 14,898,326	$ 0
Reverse stock split description				On July 16, 2018, the Company effected a one-for-21.4 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company’s redeemable convertible preferred stock, and on August 15, 2018, the Company effected an additional one-for-two reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company’s redeemable convertible preferred stock. Accordingly, all share and per share amounts for all periods presented in the accompanying financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect these reverse stock splits and adjustments of the preferred stock conversion ratios.
Reverse stock split conversion ratio	50.00%	4.60%
Initial Public Offering
Organization And Basis Of Presentation [Line Items]
Number of units sold			3,864,000
Sale of stock, description of transaction				Each unit consisting of one share of common stock and one warrant to purchase one share of its common stock.
Offering price per unit			$ 6.125
Net cash proceeds after deducting underwriting discounts and commissions			$ 19,400,000
Underwriters' discounts and commissions			2,200,000
Offering expenses			$ 2,100,000
Number of common stock issuable upon conversion of convertible preferred stock			2,850,280
Conversion of preferred stock warrants into common stock warrants			$ 84,676
Fair value of warrants			$ 400,000
Percentage of offering price per unit			100.00%
Initial Public Offering | Common Stock
Organization And Basis Of Presentation [Line Items]
Number of units sold				3,864,000
Outstanding convertible promissory notes and accrued interest converted, amount			$ 14,900,000
Outstanding convertible promissory notes and accrued interest converted, shares			3,239,294	2,850,280
Initial Public Offering | Maximum
Organization And Basis Of Presentation [Line Items]
Issuance of warrants to underwriters to purchase of common stock			115,920
Underwriters Over-Allotment Option
Organization And Basis Of Presentation [Line Items]
Number of units sold			504,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Schedule of Allowance for Doubtful Accounts (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Accounts receivable	$ 4,000,924	$ 3,614,214
Provision	0	(262,000)
Accounts receivable, net	$ 4,000,924	$ 3,352,214

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2018USD ($)Segment$ / sharesshares	Sep. 30, 2017USD ($)	Dec. 31, 2017USD ($)
Summary Of Significant Accounting Policies [Line Items]
Inventory write-down		$ 1,287,000	$ 364,437
Number of operating segments | Segment		1
Convertible Preferred Stock Warrants
Summary Of Significant Accounting Policies [Line Items]
Fair value of common warrants issued	$ 0	$ 0
Initial Public Offering
Summary Of Significant Accounting Policies [Line Items]
Deferred public offering costs	4,659,369	4,659,369
Fair value of common warrants issued	$ 382,347	$ 382,347
Number of warrants issued to purchase common stock | shares	115,290	115,290
Warrants exercise price | $ / shares	$ 9.1875	$ 9.1875
Irys Instruments
Summary Of Significant Accounting Policies [Line Items]
Inventory net realizable value	$ 0	$ 0		$ 1,300,000
Inventory write-down	$ 1,300,000			$ 400,000
Accounts Receivable | Ultravision Technology Ltd.
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage		16.00%		21.00%
Accounts Receivable | BioStar Company
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage		0.00%		15.00%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Components of Inventories (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Materials and supplies	$ 242,783	$ 203,085
Finished Goods	2,372,029	1,490,657
Total	$ 2,614,812	$ 1,693,742

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	4,430,150	1,275,884	4,430,150	1,275,884
Common Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	415,137	420,678	415,137	420,678
Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	4,015,013	855,206	4,015,013	855,206

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value Measurement of Assets And Liabilities (Details) - Fair Value on Recurring Basis - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	$ 20,657,038	$ 1,021,897
Total liabilities	0	3,898,944
Cash and Cash Equivalents
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	20,657,038	1,021,897
Preferred Stock Warrant Liability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total liabilities	0	3,898,944
Fair Value Measurement Using Quoted Prices In Active Markets For Identical Assets Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	20,657,038	1,021,897
Total liabilities	0	0
Fair Value Measurement Using Quoted Prices In Active Markets For Identical Assets Level 1 | Cash and Cash Equivalents
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	20,657,038	1,021,897
Fair Value Measurement Using Quoted Prices In Active Markets For Identical Assets Level 1 | Preferred Stock Warrant Liability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total liabilities	0	0
Fair Value Measurement Using Significant Other Observable Inputs Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	0
Total liabilities	0	0
Fair Value Measurement Using Significant Other Observable Inputs Level 2 | Cash and Cash Equivalents
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	0
Fair Value Measurement Using Significant Other Observable Inputs Level 2 | Preferred Stock Warrant Liability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total liabilities	0	0
Fair Value Measurement Using Significant Unobservable Inputs Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	0
Total liabilities	0	3,898,944
Fair Value Measurement Using Significant Unobservable Inputs Level 3 | Cash and Cash Equivalents
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	0
Fair Value Measurement Using Significant Unobservable Inputs Level 3 | Preferred Stock Warrant Liability
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total liabilities	$ 0	$ 3,898,944

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - Initial Public Offering	1 Months Ended
	Aug. 31, 2018shares
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants exercisable for convertible preferred stock	0
Warrants previously exercisable for preferred stock	37,200,000
Warrants expired on the effective date	35,700,000
Remaining warrants previously exercisable for preferred stock adjusted to become exercisable for common stock	1,500,000

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Changes in Level 3 Liabilities (Details) - Warrants - Fair Value Measurement Using Significant Unobservable Inputs Level 3 - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance	$ 3,898,944	$ 4,650,877
Expiration of Series A warrants		(1,424)
Change in fair value of preferred stock warrants	(3,991,081)	(750,509)
Balance		$ 3,898,944
Issuance of warrants in connection with debt (unaudited)	176,813
Conversion of preferred stock warrants to common stock warrants due to IPO (unaudited)	$ (84,676)

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Quantitative Information Relating to Unobservable Inputs (Details) - Black-Scholes-Merton Model	Dec. 31, 2017$ / shares
Fair value of Series A preferred stock
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants to purchase, Fair value preferred stock	$ 0.66
Fair value of Series B-1 preferred stock
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants to purchase, Fair value preferred stock	0.36
Fair value of Series D preferred stock
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants to purchase, Fair value preferred stock	0.48
Fair value of Series D-1 preferred stock
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants to purchase, Fair value preferred stock	$ 0.48
Risk-free interest rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants to purchase, Risk-free interest rate	1.75
Volatility
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants to purchase, Risk-free interest rate	54.60
Measurement Input, Expected Term
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants to purchase, Expected life (in years)	7 months 6 days

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Prepaid Expense And Other Assets Current [Abstract]
Prepayment to supplier	$ 249,071	$ 492,330
Other current assets	1,098,703	579,182
Total	$ 1,347,774	$ 1,071,512

Property and Equipment, net - S

Property and Equipment, net - Schedule of Property and Equipment, net (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 7,088,141	$ 6,927,353
Less accumulated depreciation and amortization	(5,038,885)	(3,921,565)
Property and equipment, net	2,049,256	3,005,788
Computer and Office Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	476,402	476,402
Lab Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	4,156,519	3,995,731
Service Equipment Placed at Customer Sites
Property Plant And Equipment [Line Items]
Property and equipment, gross	594,553	594,553
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 1,860,667	$ 1,860,667

Property and Equipment, net - A

Property and Equipment, net - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Property Plant And Equipment [Abstract]
Depreciation and amortization expense	$ 391,246	$ 240,551	$ 1,169,801	$ 964,932

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Accrued Liabilities Current [Abstract]
Accrued expenses	$ 2,185,354	$ 2,596,137
Accrued bonus	629,936	912,757
Total	$ 2,815,290	$ 3,508,894

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information - Western Alliance LSA (Details) - USD ($)	Jun. 29, 2018	Jun. 13, 2018	Dec. 09, 2016	Mar. 08, 2016	Sep. 30, 2018	Aug. 31, 2018	Feb. 28, 2018	Dec. 31, 2017	Nov. 20, 2017
Debt Instrument [Line Items]
Debt issuance cost and facility fee				$ 113,542
Percentage of total amount borrowed				3.25%
Current Liabilities
Debt Instrument [Line Items]
Debt discount charge				$ 227,500
Western Alliance LSA
Debt Instrument [Line Items]
Repayment of outstanding term loan	$ 7,000,000
Debt discount charge								$ 227,500
Default to secure minimum sale or issuance of equity securities or subordinated debt								15,000,000
Reclassified total loan balance to current liabilities								$ 6,700,000
Required secure funding		$ 5,000,000					$ 21,000,000
Total cash collected from customers		$ 2,500,000
Western Alliance LSA | Series D Convertible Preferred Stock
Debt Instrument [Line Items]
Warrants to purchase, Fair value preferred stock						$ 20.54
Shares of common stock						11,925
Warrants expiration date					Mar. 8, 2026
Western Alliance LSA | Current Liabilities
Debt Instrument [Line Items]
Amendment fee									$ 17,500
Term Loan | Series D-1 Convertible Preferred Stock
Debt Instrument [Line Items]
Warrants to purchase, Fair value preferred stock						$ 20.55
Shares of common stock						6,814
Warrants expiration date					Dec. 9, 2026
Term Loan | Western Alliance LSA
Debt Instrument [Line Items]
Proceeds from loan				$ 7,000,000
Term Loan | Western Alliance LSA | Series D Convertible Preferred Stock
Debt Instrument [Line Items]
Warrants to purchase shares issued				510,417
Warrants to purchase, Fair value preferred stock				$ 0.48
Debt discount and amortization of interest expense				$ 65,384
Term Loan | Western Alliance LSA | Series D-1 Convertible Preferred Stock
Debt Instrument [Line Items]
Warrants to purchase shares issued			291,667
Debt discount and amortization of interest expense			$ 34,300
Term Loan | Square One Loan And Security Agreement
Debt Instrument [Line Items]
Repayment of outstanding term loan				$ 5,000,000

Long-Term Debt - Additional I_2

Long-Term Debt - Additional Information - MidCap Financial CSA (Details)	Jun. 29, 2018USD ($)Tranche$ / sharesshares	Sep. 30, 2018USD ($)	Aug. 31, 2018$ / sharesshares
Term Loan | Series D-1 Convertible Preferred Stock
Debt Instrument [Line Items]
Warrants to purchase, Fair value preferred stock | $ / shares			$ 20.55
Shares of common stock | shares			6,814
Warrants expiration date		Dec. 9, 2026
MidCap Financial CSA
Debt Instrument [Line Items]
Term loan facility available	$ 15,000,000
Number of tranches | Tranche	3
Annual interest rate bears	7.50%
Annual interest rate bears description		one month LIBOR plus 7.5%,
Maturity date description		The loan has a 60-month term, with interest only for the first 18 months and straight-line amortization of principal and interest for the remaining 42 months.
LIBOR subject to floor rate	1.50%
Debt instrument maturity period	60 months
Debt instrument interest only portion maturity period	18 months
Debt instrument principal and interest maturity period	42 months
Debt instrument maturity date	Jul. 1, 2023
Debt issuance fees paid	$ 300,000
Prepayment fee percentage	4.00%
Additional amount invested in term loan facility		$ 1,000,000
MidCap Financial CSA | Term Loan | Series D-1 Convertible Preferred Stock
Debt Instrument [Line Items]
Warrants to purchase shares | shares	625,000
Warrants to purchase, Fair value preferred stock | $ / shares	$ 0.48		$ 20.55
Warrant exercisable and expires	Jun. 29, 2028
Debt discount and amortization of interest expense	$ 200,000
Shares of common stock | shares			14,603
Warrants expiration date		Jun. 29, 2028
MidCap Financial CSA | Term Loan | Series D-1 Convertible Preferred Stock | Measurement Input, Expected Term
Debt Instrument [Line Items]
Fair value assumptions term	10 years
MidCap Financial CSA | Term Loan | Series D-1 Convertible Preferred Stock | Risk-free interest rate
Debt Instrument [Line Items]
Fair value assumptions	0.0283
MidCap Financial CSA | Term Loan | Series D-1 Convertible Preferred Stock | Volatility
Debt Instrument [Line Items]
Fair value assumptions	0.59
MidCap Financial CSA | Other Long-term Liabilities
Debt Instrument [Line Items]
Debt discount charge		$ 400,000
MidCap Financial CSA | First Year
Debt Instrument [Line Items]
Prepayment fee percentage	4.00%
MidCap Financial CSA | Second Year
Debt Instrument [Line Items]
Prepayment fee percentage	3.00%
MidCap Financial CSA | Thereafter
Debt Instrument [Line Items]
Prepayment fee percentage	2.00%
MidCap Financial CSA | Tranche 1
Debt Instrument [Line Items]
Term loan facility available	$ 10,000,000
Term loan facility borrowed from Tranche 1	10,000,000
MidCap Financial CSA | Tranche 2
Debt Instrument [Line Items]
Term loan facility available	2,500,000
Trailing twelve month revenue	12,500,000
MidCap Financial CSA | Tranche 3
Debt Instrument [Line Items]
Term loan facility available	2,500,000
Trailing twelve month revenue	16,000,000
Western Alliance LSA
Debt Instrument [Line Items]
Repayment of outstanding term loan	$ 7,000,000

Long-Term Debt - Additional I_3

Long-Term Debt - Additional Information - Convertible Notes (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Aug. 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Aug. 02, 2018	Jun. 29, 2018	Jun. 28, 2018	Feb. 09, 2018
Debt Instrument [Line Items]
Outstanding convertible promissory notes and accrued interest converted, amount				$ 14,898,326	$ 0
Convertible notes outstanding		$ 0		0
Non-cash interest expense related to debt discount amortization and accretion of end of term fees		$ 52,194	$ 21,558	$ 121,984	$ 66,241
Convertible Notes
Debt Instrument [Line Items]
Outstanding convertible promissory notes and accrued interest converted, amount	$ 14,900,000
Convertible Notes | Common Stock
Debt Instrument [Line Items]
Outstanding convertible promissory notes and accrued interest converted, shares	3,239,294
Note Purchase Agreement | Convertible Notes
Debt Instrument [Line Items]
Increase the principal amount available for issuance						$ 18,400,000	$ 19,400,000	$ 18,400,000
Maturity date				Sep. 30, 2018
Note Purchase Agreement | Convertible Notes | Maximum
Debt Instrument [Line Items]
Original principal amount									$ 16,000,000

Long-Term Debt - Schedule of De

Long-Term Debt - Schedule of Debt and Unamortized Discount Balances (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Current portion of long-term debt	$ 0	$ 6,729,752
Long-term debt	9,008,337	0
Western Alliance LSA
Debt Instrument [Line Items]
Term loan face value		7,000,000
Fair value of warrant		(99,684)
End of term charge		(227,500)
Capitalized debt issuance costs		(131,042)
Accretion of debt issuance costs and end of term charge		148,225
Accretion of warrant fair value		39,753
Balance		6,729,752
Current portion of long-term debt		$ 6,729,752
MidCap Financial CSA
Debt Instrument [Line Items]
Term loan face value	10,000,000
Fair value of warrant	(176,813)
End of term charge	(400,000)
Capitalized debt issuance costs	(467,044)
Accretion of debt issuance costs and end of term charge	43,352
Accretion of warrant fair value	8,842
Balance	9,008,337
Long-term debt	9,008,337
End of term charge	$ (400,000)

Long-Term Debt - Schedule of Fu

Long-Term Debt - Schedule of Future Minimum Payments Including Interest (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Current portion of long-term debt	$ 0	$ 6,729,752
Long-term debt	9,008,337	$ 0
MidCap Financial CSA
Debt Instrument [Line Items]
2,018	243,900
2,019	975,600
2,020	3,704,986
2,021	3,426,243
2022-2023	5,016,721
Total minimum loan payments	13,367,450
Unamortized interest	(2,967,450)
End of term charge	(400,000)
Warrant fair value	(167,972)
Capitalized debt issuance costs and end of term charge	(823,691)
Balance	9,008,337
Long-term debt	$ 9,008,337

Stockholders' Deficit - Additio

Stockholders' Deficit - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		10 Months Ended	12 Months Ended
	Aug. 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Nov. 30, 2017	Dec. 31, 2017	Aug. 23, 2018	Jul. 31, 2018	Dec. 31, 2016
Equity [Line Items]
Common stock, shares authorized		200,000,000		200,000,000			243,160,120	200,000,000
Common stock, par value		$ 0.0001		$ 0.0001			$ 0.0001	$ 0.0001
Preferred stock, shares authorized		10,000,000		10,000,000			10,000,000	10,000,000
Preferred stock, par value		$ 0.0001		$ 0.0001			$ 0.0001	$ 0.0001
Common stock, shares issued		10,032,687		10,032,687			77,257
Proceeds from option exercises				$ 3,499	$ 1,500
Common stock initially reserved for future issuance		5,689,435		5,689,435
Unrecognized compensation cost related to outstanding employee options		$ 132,726		$ 132,726
Unrecognized compensation cost related to outstanding employee options, period for recognition				1 year 1 month 6 days
Number of common stock purchased under plan				0
2018 Employee Stock Purchase Plan
Equity [Line Items]
Common stock initially reserved for future issuance	175,000
Incremental rate at which the shares reserved for issuance increase				1.00%
Employee Options
Equity [Line Items]
Shares, granted		0	17,769	385	422,706
Exercise price		$ 1.28	$ 1.28	$ 6	$ 1.28
Total grant date fair value of vested options		$ 50,584	$ 60,515	$ 161,897	$ 232,915
Weighted-average grant date fair value			$ 0.67	$ 2.99	$ 0.66
2018 Equity Incentive Plan
Equity [Line Items]
Common stock initially reserved for future issuance	1,499,454	1,084,285		1,084,285
Number of new shares issued under plan	1,000,000
Incremental rate at which the shares reserved for issuance increase				5.00%
Shares of common stock subject to outstanding options		415,137		415,137
Maximum | 2018 Employee Stock Purchase Plan
Equity [Line Items]
Common stock initially reserved for future issuance	220,000
Company Valued $91 Million or Below
Equity [Line Items]
Liquidation preferences, description				the Liquidation Preference was equal to the applicable Original Issue Price for such shares plus the amount of any declared but unpaid dividends
Company Valued $91 Million or Below | Minimum
Equity [Line Items]
Company value		$ 91,000,000		$ 91,000,000
Company Valued Greater than $91 Million
Equity [Line Items]
Liquidation preferences, description				the Liquidation Preference was equal to the applicable Original Issue Price for such shares plus the amount of any declared but unpaid dividends, with the first $10 million of proceeds above $91 million distributed to the holders of the Series D and D-1 convertible preferred stock on a pro rata basis ((i) and (ii) together, “Liquidation Preference”)
Amount distributed to the holders in excess of company's value				$ 10,000,000
Company Valued Greater than $91 Million | Maximum
Equity [Line Items]
Company value		$ 91,000,000		$ 91,000,000
Convertible Preferred Stock
Equity [Line Items]
Number of common stock issuable upon conversion of convertible preferred stock	42.8	42.8		42.8
Convertible preferred stock outstanding		0		0					121,992,497
Proceeds from issuance of convertible preferred stock				$ 15,000,000
Percentage of vote on outstanding of series preferred shares				66.67%
Shares issued, price per share		$ 6		$ 6
Preferred Stock, Dividend Rate, Percentage				8.00%
Series A Convertible Preferred Stock
Equity [Line Items]
Conversion price per share	$ 1.3995	$ 1.3995		$ 1.3995
Convertible preferred stock outstanding		0		0			345,587			345,587
Original issuance price		$ 2.733		$ 2.733
Series B Convertible Preferred Stock
Equity [Line Items]
Conversion price per share	1.3995	$ 1.3995		$ 1.3995
Convertible preferred stock outstanding		0		0			8,058,170			8,058,170
Original issuance price		$ 1.3995		$ 1.3995
Series B-1 Convertible Preferred Stock
Equity [Line Items]
Conversion price per share	1.3995	$ 1.3995		$ 1.3995
Convertible preferred stock outstanding		0		0			3,437,950			3,437,950
Original issuance price		$ 1.3995		$ 1.3995
Series C Convertible Preferred Stock
Equity [Line Items]
Conversion price per share	1.4043	$ 1.4043		$ 1.4043
Convertible preferred stock outstanding		0		0			23,357,047			23,357,047
Original issuance price		$ 1.4043		$ 1.4043
Series D Convertible Preferred Stock
Equity [Line Items]
Conversion price per share	0.48	$ 0.48		$ 0.48
Convertible preferred stock outstanding		0		0			20,652,486			20,652,486
Original issuance price		$ 0.48		$ 0.48
Series D-1 Convertible Preferred Stock
Equity [Line Items]
Conversion price per share	$ 0.48	$ 0.48		$ 0.48		$ 0.48
Convertible preferred stock outstanding		0		0			66,141,257			29,166,671
Temporary equity shares sold and issued						36,974,586	36,974,586
Proceeds from issuance of convertible preferred stock						$ 17,750,000
Temporary equity stock issuance costs						$ 154,191
Original issuance price		$ 0.48		$ 0.48
Common Stock
Equity [Line Items]
Share issued exercise options		1,068	1,168	1,856	1,168		7,079
Proceeds from option exercises		$ 1,116	$ 1,500	$ 3,499	$ 1,500

Stockholders' Deficit - Summary

Stockholders' Deficit - Summary of Stock Option Activity Under 2018 Plan and 2006 Plan (Details) - 2018 Employee Stock Purchase Plan - 2018 Plan and 2006 Plan	9 Months Ended	12 Months Ended
	Sep. 30, 2018USD ($)$ / sharesshares	Dec. 31, 2017$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, outstanding beginning balance | shares	436,341
Shares, granted (unaudited) | shares	385
Shares, exercised (unaudited) | shares	(1,856)
Shares, cancelled/expired (unaudited) | shares	(19,733)
Shares, outstanding ending balance (unaudited) | shares	415,137	436,341
Shares, vested and expected to vest at September 30, 2018 (unaudited) | shares	399,705
Shares, vested and exercisable at September 30, 2018 (unaudited) | shares	261,487
Weighted-Average Exercise Price, outstanding beginning balance | $ / shares	$ 5.14
Weighted-Average Exercise Price, granted (unaudited) | $ / shares	6
Weighted-Average Exercise Price, exercised (unaudited) | $ / shares	1.28
Weighted-Average Exercise Price, cancelled/expired (unaudited) | $ / shares	9.65
Weighted-Average Exercise Price, outstanding ending balance (unaudited) | $ / shares	4.99	$ 5.14
Weighted-Average Exercise Price, vested and expected to vest at September 30, 2018 (unaudited) | $ / shares	5.14
Weighted-Average Exercise Price, vested and exercisable at September 30, 2018 (unaudited) | $ / shares	$ 6.73
Weighted-Average Remaining Contractual Term, outstanding balance	8 years 2 months 12 days	9 years
Weighted-Average Remaining Contractual Term, vested and expected to vest at September 30, 2018 (unaudited)	8 years 2 months 12 days
Weighted-Average Remaining Contractual Term, vested and exercisable at September 30, 2018 (unaudited)	8 years 1 month 6 days
Aggregate Intrinsic Value, exercised (unaudited) | $	$ 4,571
Aggregate Intrinsic Value, Outstanding at September 30, 2018 (unaudited) | $	2,589,204
Aggregate Intrinsic Value, Vested and expected to vest at September 30, 2018 (unaudited) | $	2,487,288
Aggregate Intrinsic Value, Vested and exercisable at September 30, 2018 (unaudited) | $	$ 1,580,698

Stockholders' Deficit - Summa_2

Stockholders' Deficit - Summary of Recognized Stock-Based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 53,125	$ 24,125	$ 160,551	$ 241,971
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	43,363	18,564	131,900	162,420
General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 9,762	$ 5,561	$ 28,651	$ 79,551

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Weighted-Average Assumptions in Black -Scholes Option Pricing Model (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	1.80%	2.50%	2.50%
Expected volatility	58.00%	63.00%	58.00%
Expected term (in years)	5 years 3 months 18 days	4 years
Expected dividend yield	0.00%	0.00%	0.00%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)			5 years 1 month 6 days
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)			5 years 3 months 18 days

Stockholders' Deficit - Sched_2

Stockholders' Deficit - Schedule of Common Stock Reserved for Future Issuance (Details)	Sep. 30, 2018shares
Class Of Stock [Line Items]
Common stock initially reserved for future issuance	5,689,435
Stock Options Issued and Outstanding
Class Of Stock [Line Items]
Common stock initially reserved for future issuance	415,137
Authorized for Future Stock Awards, Option Grants, or Employee Stock Purchase Program
Class Of Stock [Line Items]
Common stock initially reserved for future issuance	1,259,285
Common Warrants
Class Of Stock [Line Items]
Common stock initially reserved for future issuance	4,015,013

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Commitments and Contingencies [Line Items]
Operating lease amended date			Jul. 1, 2015
Operating lease expiration date			Dec. 31, 2020
Rent expense	$ 147,522	$ 147,522	$ 442,566	$ 442,566
Amortization of the leasehold incentive obligation	56,263	56,263	168,789	168,789
Amount of royalty expense paid	76,846	$ 75,960	$ 295,246	$ 235,455
Annual future minimum royalty payments							$ 70,000
Future minimum royalty payments, extended term			Nov. 29, 2026
Contractual commitment with supplier to purchase products remainder of fiscal year	100,000		$ 100,000
Loss contingency accrual amount	$ 0		$ 0
Scenario, Forecast
Commitments and Contingencies [Line Items]
Contractual commitment with supplier to purchase products remainder of fiscal year					$ 100,000	$ 100,000

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Future Minimum Lease Payments Required under Non-Cancelable Leases (Details)	Sep. 30, 2018USD ($)
Commitments And Contingencies Disclosure [Abstract]
2018 (3 months remaining)	$ 206,721
2,019	862,656
2,020	902,412
Total minimum lease payments	$ 1,971,789

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Effective income tax rate			(0.06%)	(0.10%)
Federal, state, and foreign income tax expense/(benefit)	$ (2,978)	$ (4,738)	$ 6,304	$ 17,620
Ownership change in series of transactions period			3 years
Minimum percentage of change in ownership			50.00%

Employee Benefits - Additional

Employee Benefits - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Compensation And Retirement Disclosure [Abstract]
Defined contribution plan name			401(k)
Contribution amount	$ 78,020	$ 97,414	$ 211,185	$ 334,988